Intact Bioactivities and Improved Pharmacokinetic of the SL335-IFN- β-1a Fusion Protein that Created by Genetic Fusion of SL335, a Human Anti-serum Albumin Fab, and Human Interferon-β.

In conclusion, our results clearly demonstrated that SL335-IFN-β-1a is worthy of further development as an alternative long-acting IFN-β therapeutic. PMID: 30684504 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30684504?dopt=Abstract

Source: Immunology Letters - January 23, 2019 Category: Allergy & Immunology Authors: Ji SI, Park JH, You HG, Chi HJ, Bang YW, Cha SH Tags: Immunol Lett Source Type: research